

## ODB FORMULARY – EDITION NO. 43, Summary of Changes – May 2019

### SUMMARY OF PRODUCT CHANGES

We are pleased to provide you with the Summary of Changes – May 2019 to Edition No. 43 of the Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary), which becomes effective **May 31, 2019**. The Edition No. 43 document will be posted on the Ministry's website [http://www.health.gov.on.ca/en/pro/programs/drugs/edition\\_43.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx) by May 31, 2019.

#### Listing Changes

- 5 multiple source drug molecules (6 DINs)
- 1 Off-Formulary Interchangeable (OFI) drug molecule (1 DIN)
- 3 drug molecules (6 DINs) and one existing drug molecule (1 DIN) with an additional indication funded through the Exceptional Access Program
- 1 drug molecule (1 DIN) and 2 existing drug molecules (3 DINs) in a combination treatment funded through the New Drug Funding Program
- 1 drug molecule (3 DINs) with funding status change

#### Multiple Source Products

Apo-Dabigatran 110mg, 150mg Cap	APX
Mar-Dapsone 100mg Tab	MAR
Mint-Abacavir 300mg Tab	MIN
Odan-Sodium Polystyrene Sulfonate Powder 454g Pk	ODN
PRZ-Domperidone 10mg Tab	PRZ

#### Exceptional Access Program (EAP) Products

##### **Actemra (tocilizumab) 162mg/0.9mL PFS (HLR) – Effective Date: April 17, 2019**

For the treatment of Giant Cell Arteritis according to clinical criteria.

##### **Alecensaro (alectinib) 150mg Cap (HLR) – Effective Date: April 17, 2019**

For the treatment of Non-Small Cell Lung Cancer according to clinical criteria.

##### **Galafold (migalastat) 123mg Cap (AMT) – Effective Date: May 13, 2019**

For the treatment of Fabry disease according to clinical criteria.

##### **Venclexta (venetoclax) 10mg, 50mg, 100mg, Starter Pk Tab (ABV) – Effective Date: May 13, 2019**

For the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma according to clinical criteria.

The reimbursement criteria for the above products will be included on the list of Frequently Requested Drugs, which can be found on the Ministry's website:

[http://www.health.gov.on.ca/en/pro/programs/drugs/pdf/frequently\\_requested\\_drugs.pdf](http://www.health.gov.on.ca/en/pro/programs/drugs/pdf/frequently_requested_drugs.pdf)

#### New Drug Funding Program (NDFP) Products

##### **Bavencio (avelumab) 200mg/10mL Single Use Vial (EMD) – Effective Date: April 18, 2019**

For the treatment of metastatic Merkel cell carcinoma according to clinical criteria.

**Opdivo (nivolumab) 10mg/mL Inj Sol – 4mL, 10mL Pk (BMS) – Effective Date: May 15, 2019**

**Yervoy (ipilimumab) 5mg/mL Inj Sol – 10mL, 40mL Pk (BMS) – Effective Date: May 15, 2019**

For metastatic renal cell carcinoma as a combination treatment according to clinical criteria.

Please refer to the Cancer Care Ontario website

(<https://www.cancercareontario.ca/en/drugformulary/drugs>) for further details on the reimbursement criteria for NDFP products.

### **Funding Status Changes**

#### **Exceptional Access Program to General Benefit**

**Lupin-Estradiol 0.5mg, 1mg, 2mg Tab (LUP)**

### **Reminder - Delisting from the Formulary**

#### **Vancomycin 500mg/vial, 1g/vial Inj (FKC) – Effective with the June 2019 Formulary Update**

Pharmacists are encouraged to plan accordingly and to transition patients as necessary to ensure continuity in drug therapy for their patients, as well as counsel affected patients appropriately.

The Ministry has posted a new file with the listing changes for download and review (Edition No. 43, Summary of Changes – May 2019). It is accessible from the Ministry's website: [http://www.health.gov.on.ca/en/pro/programs/drugs/edition\\_43.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx).

In addition, the Formulary, Summaries of Changes and Bulletins, including a searchable electronic version of the Formulary (e-Formulary), are also accessible from the ministry's website: <https://www.formulary.health.gov.on.ca/formulary/> - The e-Formulary will be updated on the effective date – May 31, 2019.

We appreciate your continued cooperation in making these benefit adjustments.